Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational Model

PLoS Computational Biology

Volumn 11, Issue 6, 2015, Pages

  Clegg, Lindsay Wendel ^a   Mac Gabhann, Feilim ^a,b  

^a Johns Hopkins University   (United States)

^b Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BLOOD VESSELS; CELL CULTURE; CELL SIGNALING; CHEMICAL ACTIVATION; COMPUTATION THEORY; COMPUTATIONAL METHODS; ENDOTHELIAL CELLS;

COMPUTATIONAL MODELLING; IMMOBILIZED LIGANDS; ISOFORMS; MATRIX BINDING; NEUROPILINS; RECEPTOR TRAFFICKING; SITE-SPECIFIC; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR REMODELING; VESSEL NETWORKS;

PHOSPHORYLATION;

NEUROPILIN 1; PHOSPHATASE; TYROSINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENDOSOME; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; MATHEMATICAL COMPUTING; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIMULATION; ANIMAL; BIOLOGICAL MODEL; BIOLOGY; CHEMISTRY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; COMPUTATIONAL BIOLOGY; ENDOSOMES; HUMANS; MICE; MODELS, BIOLOGICAL; NEUROPILIN-1; PHOSPHORYLATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84933070288     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004158     Document Type: Article

References (85)

1. Eming SA, Hubbell JA, Extracellular matrix in angiogenesis: dynamic structures with translational potential. Experimental Dermatology. 2011;20(7):605–13. doi: 10.1111/j.1600-0625.2011.01309.x WOS:000292106700014. 21692861
2. Lovett M, Lee K, Edwards A, Kaplan DL, Vascularization Strategies for Tissue Engineering. Tissue Engineering Part B-Reviews. 2009;15(3):353–70. doi: 10.1089/ten.teb.2009.0085 WOS:000269621100010. 19496677
3. Auger FA, Gibot L, Lacroix D, The Pivotal Role of Vascularization in Tissue Engineering. Annual Review of Biomedical Engineering, Vol 15. 2013;15:177–200. doi: 10.1146/annurev-bioeng-071812-152428 WOS:000323896000009. 23642245
4. Mac Gabhann F, Qutub AA, Annex BH, Popel AS, Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews-Systems Biology and Medicine. 2010;2(6):694–707. doi: 10.1002/wsbm.92 WOS:000283713500006. 20890966
5. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. American Journal of Pathology. 2004;164(6):1935–47. doi: 10.1016/s0002-9440(10)63754-6 WOS:000221601000008. 15161630
6. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H, The Role of Vascular Endothelial Growth Factor in Wound Healing. Journal of Surgical Research. 2009;153(2):347–58. doi: 10.1016/j.jss.2008.04.023 WOS:000265585100024. 19027922
7. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, DiPietro LA, Regulation of scar formation by vascular endothelial growth factor. Laboratory Investigation. 2008;88(6):579–90. doi: 10.1038/labinvest.2008.36 WOS:000256114600002. 18427552
8. Anderson SM, Shergill B, Barry ZT, Manousiouthakis E, Chen TT, Botvinick E, et al. VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF. Integrative Biology. 2011;3(9):887–96. doi: 10.1039/c1ib00037c WOS:000294448600002. 21826315
9. Simons M, An Inside View: VEGF Receptor Trafficking and Signaling. Physiology. 2012;27(4):213–22. doi: 10.1152/physiol.00016.2012 WOS:000307673500005. 22875452
10. Berger P, Ballmer-Hofer K, The reception and the party after how vascular endothelial growth factor receptor 2 explores cytoplasmic space. Swiss Medical Weekly. 2011;141:w13318. doi: 10.4414/smw.2011.13318 WOS:000298157900001. 22180219
11. Martino MM, Briquez PS, Güç E, Tortelli F, Kilarski WW, Metzger S, et al. Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing. Science. 2014;343(6173):885–8. doi: 10.1126/science.1247663 24558160
12. Mac Gabhann F, Popel AS, Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(1):H459–74. doi: 10.1152/ajpheart.00637.2006 WOS:000243383300055. 16980341
13. Kut C, Mac Gabhann F, Popel AS, Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. British Journal of Cancer. 2007;97(7):978–85. doi: 10.1038/sj.bjc.6603923 WOS:000249882000022. 17912242
14. Mac Gabhann F, Popel AS, Systems biology of vascular endothelial growth factors. Microcirculation (New York, NY: 1994). 2008;15(8):715–38. MEDLINE:18608994. doi: 10.1080/10739680802095964
15. Yao C, Roderfeld M, Rath T, Roeb E, Bernhagen J, Steffens G, The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices. Biomaterials. 2006;27(8):1608–16. doi: 10.1016/j.biomaterials.2005.08.037 WOS:000234731900048. 16183114
16. Wijelath ES, Murray J, Rahman S, Patel Y, Ishida A, Strand K, et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circulation Research. 2002;91(1):25–31. doi: 10.1161/01.res.0000026420.22406.79 WOS:000176944100006. 12114318
17. Tabata Y, Miyao M, Ozeki M, Ikada Y, Controlled release of vascular endothelial growth factor by use of collagen hydrogels. Journal of Biomaterials Science-Polymer Edition. 2000;11(9):915–30. doi: 10.1163/156856200744101 WOS:000165637500002. 11211086
18. Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain—Enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circulation Research. 2006;99(8):853–60. doi: 10.1161/01.res.0000246849.17887.66 WOS:000241217000011. 17008606
19. Wijelath E, Namekata M, Murray J, Furuyashiki M, Zhang S, Coan D, et al. Multiple Mechanisms for Exogenous Heparin Modulation of Vascular Endothelial Growth Factor Activity. Journal of Cellular Biochemistry. 2010;111(2):461–8. doi: 10.1002/jcb.22727 WOS:000282482400022. 20524207
20. Vempati P, Popel AS, Mac Gabhann F, Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning. Cytokine & Growth Factor Reviews. 2014;25(1):1–19. doi: 10.1016/j.cytogfr.2013.11.002
21. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA, Differential expression of VEGF isoforms in mouse during development and in the adult. Developmental Dynamics. 2001;220(2):112–21. doi: 10.1002/1097-0177(2000) WOS:000166693000003. 11169844
22. Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS, Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Molecular and Cellular Biology. 2000;20(19):7282–91. doi: 10.1128/mcb.20.19.7282-7291.2000 WOS:000089268700025. 10982845
23. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML, Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. Journal of Cell Biology. 2005;169(4):681–91. doi: 10.1083/jcb.200409115 WOS:000229305400016. 15911882
24. Tan WH, Popel AS, Mac Gabhann F, Computational model of VEGFR2 pathway to ERK activation and modulation through receptor trafficking. Cellular signalling. 2013;25(12):2496–510. doi: 10.1016/j.cellsig.2013.08.015 MEDLINE:23993967. 23993967
25. Wan Hua T, Popel AS, Mac Gabhann F, Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation. PLoS One. 2013;8(6):e67438. doi: 10.1371/journal.pone.0067438 WOS:000320846500140. 23805312
26. Fujio Y, Walsh K, Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. Journal of Biological Chemistry. 1999;274(23):16349–54. doi: 10.1074/jbc.274.23.16349 WOS:000080668600053. 10347193
27. Sase H, Watabe T, Kawasaki K, Miyazono K, Miyazawa K, VEGFR2-PLC gamma 1 axis is essential for endothelial specification of VEGFR2(+) vascular progenitor cells. Journal of Cell Science. 2009;122(18):3303–11. doi: 10.1242/jcs.049908 WOS:000269521900012. 19706681
28. Takahashi T, Yamaguchi S, Chida K, Shibuya M, A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO Journal. 2001;20(11):2768–78. doi: 10.1093/emboj/20.11.2768 WOS:000169231800015. 11387210
29. Chen TT, Luque A, Lee S, Anderson SM, Segura T, Iruela-Arispe ML, Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. Journal of Cell Biology. 2010;188(4):595–609. doi: 10.1083/Jcb.200906044 ISI:000274723800016. 20176926
30. Lamalice L, Houle F, Huot J, Phosphorylation of Tyr(1214) within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. Journal of Biological Chemistry. 2006;281(45):34009–20. doi: 10.1074/jbc.M603928200 WOS:000241767600021. 16966330
31. Koch S, Neuropilin signalling in angiogenesis. Biochemical Society Transactions. 2012;40:20–5. doi: 10.1042/bst20110689 WOS:000300136600005. 22260660
32. Mac Gabhann F, Popel AS, Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. American Journal of Physiology-Heart and Circulatory Physiology. 2005;288(6):H2851–60. doi: 10.1152/ajpheart.01218.2004 WOS:000229139900040. 15708957
33. Lanahan A, Zhang X, Fantin A, Zhuang Z, Rivera-Molina F, Speichinger K, et al. The Neuropilin 1 Cytoplasmic Domain Is Required for VEGF-A-Dependent Arteriogenesis. Developmental Cell. 2013;25(2):156–68. doi: 10.1016/j.devcel.2013.03.019 WOS:000318327300007. 23639442
34. Salikhova A, Wang L, Lanahan AA, Liu M, Simons M, Leenders WPJ, et al. Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circulation Research. 2008;103(6):E71–E9. doi: 10.1161/circresaha.108.183327 WOS:000259252500019. 18723443
35. Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC, VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Molecular Biology of the Cell. 2011;22(15):2766–76. doi: 10.1091/mbc.E09-12-1061 WOS:000293227200010. 21653826
36. Shraga-Heled N, Kessler O, Prahst C, Kroll J, Augustin H, Neufeld G, Neuropilin-1 and neuropilin-2 enhance VEGF(121) stimulated signal transduction by the VEGFR-2 receptor. Faseb Journal. 2007;21(3):915–26. doi: 10.1096/fj.06-6277com WOS:000244686400028. 17185751
37. Bruns AF, Herbert SP, Odell AF, Jopling HM, Hooper NM, Zachary IC, et al. Ligand-Stimulated VEGFR2 Signaling is Regulated by Co-Ordinated Trafficking and Proteolysis. Traffic. 2010;11(1):161–74. doi: 10.1111/j.1600-0854.2009.01001.x WOS:000274184800014. 19883397
38. Wang Y, Pennock S, Chen XM, Wang ZX, Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Molecular and Cellular Biology. 2002;22(20):7279–90. doi: 10.1128/mcb.22.20.7279-7290.2002 WOS:000178266400029. 12242303
39. Wang Y, Pennock SD, Chen XM, Kazlauskas A, Wang ZX, Platelet-derived growth factor receptor-mediated signal transduction from endosomes. Journal of Biological Chemistry. 2004;279(9):8038–46. doi: 10.1074/jbc.M311494200 WOS:000189103300082. 14660565
40. Ballmer-Hofer K, Andersson AE, Ratcliffe LE, Berger P, Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood. 2011;118(3):816–26. doi: 10.1182/blood-2011-01-328773 WOS:000292967300045. 21586748
41. Gampel A, Moss L, Jones MC, Brunton V, Norman JC, Mellor H, VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood. 2006;108(8):2624–31. doi: 10.1182/blood-2005-12-007484 WOS:000241131700028. 16638931
42. Jopling HM, Howell GJ, Gamper N, Ponnambalam S, The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling. Biochemical and Biophysical Research Communications. 2011;410(2):170–6. doi: 10.1016/j.bbrc.2011.04.093 WOS:000292623800003. 21539813
43. Jopling HM, Odell AF, Hooper NM, Zachary IC, Walker JH, Ponnambalam S, Rab GTPase Regulation of VEGFR2 Trafficking and Signaling in Endothelial Cells. Arteriosclerosis Thrombosis and Vascular Biology. 2009;29(7):1119–24. doi: 10.1161/atvbaha.109.186239 WOS:000267102500021. 19372461
44. Sadowski L, Pilecka I, Miaczynska M, Signaling from endosomes: Location makes a difference. Experimental Cell Research. 2009;315(9):1601–9. doi: 10.1016/j.yexcr.2008.09.021 WOS:000266121200007. 18930045
45. Nakayama M, Berger P, Coordination of VEGF receptor trafficking and signaling by coreceptors. Experimental Cell Research. 2013;319(9):1340–7. doi: 10.1016/j.yexcr.2013.03.008 WOS:000319369500014. 23499743
46. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E, Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. Journal of Cell Biology. 2006;174(4):593–604. doi: 10.1083/jcb.200602080 WOS:000239986600017. 16893970
47. Goh LK, Sorkin A, Endocytosis of Receptor Tyrosine Kinases. Cold Spring Harbor Perspectives in Biology. 2013;5(5):17. doi: 10.1101/cshperspect.a017459 WOS:000318484500014.
48. Dobrowolski R, De Robertis EM, Endocytic control of growth factor signalling: multivesicular bodies as signalling organelles. Nature Reviews Molecular Cell Biology. 2012;13(1):53–60. doi: 10.1038/nrm3244 WOS:000298381700016. 22108513
49. Kappert K, Peters KG, Bohmer FD, Ostman A, Tyrosine phosphatases in vessel wall signaling. Cardiovascular Research. 2005;65(3):587–98. doi: 10.1016/j.cardiores.2004.08.016 WOS:000226858700006. 15664385
50. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D, Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: Quantitative analysis of HER2 overexpression effects. Cancer Research. 2003;63(5):1130–7. WOS:000181327700034. 12615732
51. Resat H, Ewald JA, Dixon DA, Wiley HS, An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophysical Journal. 2003;85(2):730–43. doi: 10.1016/s0006-3495(03)74516-0 WOS:000184428300006. 12885624
52. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D, Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis—Distribution of homo- and heterodimers depends on relative HER2 levels. Journal of Biological Chemistry. 2003;278(26):23343–51. doi: 10.1074/jbc.M300477200 WOS:000183638600018. 12686539
53. Vempati P, Popel AS, Mac Gabhann F, Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Systems Biology. 2011;5(59). doi: 10.1186/1752-0509-5-59 WOS:000291881200001. 21535871
54. Forsten-Williams K, Kurtagic E, Nugent MA, Complex receptor-ligand dynamics control the response of the VEGF system to protease injury. BMC Systems Biology. 2011;5(170). doi: 10.1186/1752-0509-5-170 WOS:000298914300001. 22014244
55. Vempati P, Mac Gabhann F, Popel AS, Quantifying the Proteolytic Release of Extracellular Matrix-Sequestered VEGF with a Computational Model. PLoS One. 2010;5(7):e11860. doi: 10.1371/journal.pone.0011860 WOS:000280520200024. 20686621
56. Mac Gabhann F, Popel AS, Dimerization of VEGF receptors and implications for signal transduction: A computational study. Biophysical Chemistry. 2007;128(2–3):125–39. doi: 10.1016/j.bpc.2007.03.010 WOS:000247582800004. 17442480
57. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS, A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Systems Biology. 2008;2(77). doi: 10.1186/1752-0509-2-77 WOS:000259952700001. 18713470
58. Whitaker GB, Limberg BJ, Rosenbaum JS, Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). Journal of Biological Chemistry. 2001;276(27):25520–31. doi: 10.1074/jbc.M102315200 WOS:000169800700143. 11333271
59. Anderson SM, Siegman SN, Segura T, The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching. Biomaterials. 2011;32(30):7432–43. doi: 10.1016/j.biomaterials.2011.06.027 WOS:000294829300015. 21783250
60. Mellberg S, Dimberg A, Bahram F, Hayashi M, Rennel E, Ameur A, et al. Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis. FASEB Journal. 2009;23(5):1490–502. doi: 10.1096/fj.08-123810 WOS:000266651700025. 19136612
61. Martino MM, Tortelli F, Mochizuki M, Traub S, Ben-David D, Kuhn GA, et al. Engineering the Growth Factor Microenvironment with Fibronectin Domains to Promote Wound and Bone Tissue Healing. Science Translational Medicine. 2011;3(100):100ra89. doi: 10.1126/scitranslmed.3002614 WOS:000294841400004. 21918106
62. Mattila E, Auvinen K, Salmi M, Ivaska J, The protein tyrosine phosphatase TCPTP controls VEGFR2 signalling. Journal of Cell Science. 2008;121(21):3570–80. doi: 10.1242/jcs.031898 WOS:000260266700010. 18840653
63. Zhao W, McCallum SA, Xiao Z, Zhang F, Linhardt RJ, Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. Bioscience Reports. 2012;32(1):71–81. doi: 10.1042/bsr20110077 WOS:000300536200008. 21658003
64. Dougher M, Terman BI, Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene. 1999;18(8):1619–27. doi: 10.1038/sj.onc.1202478 WOS:000078770700012. 10102632
65. Imoukhuede PI, Popel AS, Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Experimental Cell Research. 2011;317(7):955–65. doi: 10.1016/j.yexcr.2010.12.014 WOS:000288822600006. 21185287
66. Kleiman LB, Maiwald T, Conzelmann H, Lauffenburger DA, Sorger PK, Rapid Phospho-Turnover by Receptor Tyrosine Kinases Impacts Downstream Signaling and Drug Binding. Molecular Cell. 2011;43(5):723–37. doi: 10.1016/j.molcel.2011.07.014 WOS:000294593300008. 21884975
67. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. Journal of Cell Science. 2008;121(20):3487–95. doi: 10.1242/jcs.016410 WOS:000259912100021. 18843117
68. Cebe-Suarez S, Gruenewald FS, Jaussi R, Li X, Claesson-Welsh L, Spillmann D, et al. Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR. FASEB Journal. 2008;22(8):3078–86. doi: 10.1096/fj.08-107219 WOS:000258089300047. 18467594
69. Wiley HS, Anomalous Binding of Epidermal Growth Factor to A431 Cells is due to the Effect of High Receptor Densities and a Saturable Endocytic System. Journal of Cell Biology. 1988;107(2):801–10. doi: 10.1083/jcb.107.2.801 WOS:A1988P764600039. 3262110
70. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L, Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Research. 2008;68(12):4683–92. doi: 10.1158/0008-5472.can-07-6577 WOS:000256855700026. 18559514
71. Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cebe-Suarez S, et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood. 2008;112(9):3638–49. doi: 10.1182/blood-2007-12-125856 WOS:000260301800023. 18664627
72. Mac Gabhann F, Popel AS, Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLoS Computational Biology. 2006;2(12):e180. doi: 10.1371/journal.pcbi.0020180 WOS:000243482000016. 17196035
73. Rosa Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Experimental Cell Research. 2007;313(8):1561–74. doi: 10.1016/j.yexcr.2007.02.020 WOS:000246128300005. 17382929
74. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, et al. Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic. 2006;7(9):1270–82. doi: 10.1111/j.1600-0854.2006.00462.x WOS:000239695100011. 17004325
75. Prahst C, Heroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, et al. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. Journal of Biological Chemistry. 2008;283(37):25110–4. doi: 10.1074/jbc.C800137200 WOS:000259012700002. 18628209
76. Ehrbar M, Zeisberger SM, Raeber GP, Hubbell JA, Schnell C, Zisch AH, The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials. 2008;29(11):1720–9. doi: 10.1016/j.biomaterials.2007.12.002 WOS:000253619900019. 18155761
77. Martino MM, Hubbell JA, The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB Journal. 2010;24(12):4711–21. doi: 10.1096/fj.09-151282 WOS:000284824400012. 20671107
78. Porter AM, Klinge CM, Gobin AS, Covalently grafted VEGF(165) in hydrogel models upregulates the cellular pathways associated with angiogenesis. American Journal of Physiology-Cell Physiology. 2011;301(5):C1086–C92. doi: 10.1152/ajpcell.00090.2011 WOS:000296583400015. 21795519
79. Streuli CH, Akhtar N, Signal co-operation between integrins and other receptor systems. Biochemical Journal. 2009;418(3):491–506. doi: 10.1042/bj20081948 WOS:000264145300002. 19228122
80. Serini G, Napione L, Arese M, Bussolino F, Besides adhesion: new perspectives of integrin functions in angiogenesis. Cardiovascular Research. 2008;78(2):213–22. doi: 10.1093/cvr/cvn045 WOS:000255808800003. 18285512
81. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010;465(7297):487–91. doi: 10.1038/nature08995 WOS:000278043700037. 20445540
82. Tessneer KL, Pasula S, Cai X, Dong Y, McManus J, Liu X, et al. Genetic Reduction of Vascular Endothelial Growth Factor Receptor 2 Rescues Aberrant Angiogenesis Caused by Epsin Deficiency. Arteriosclerosis Thrombosis and Vascular Biology. 2014;34(2):331–7. doi: 10.1161/atvbaha.113.302586 WOS:000335607300019. 24311377
83. Lee MY, Skoura A, Park EJ, Landskroner-Eiger S, Jozsef L, Luciano AK, et al. Dynamin 2 regulation of integrin endocytosis, but not VEGF signaling, is crucial for developmental angiogenesis. Development. 2014;141(7):1465–72. doi: 10.1242/dev.104539 WOS:000333184500005. 24598168
84. Lanahan AA, Hermans K, Claes F, Kerley-Hamilton JS, Zhuang ZW, Giordano FJ, et al. VEGF Receptor 2 Endocytic Trafficking Regulates Arterial Morphogenesis. Developmental Cell. 2010;18(5):713–24. doi: 10.1016/j.devcel.2010.02.016 WOS:000278115500008. 20434959
85. Koch S, van Meeteren LA, Morin E, Testini C, Westrom S, Bjorkelund H, et al. NRP1 Presented in trans to the Endothelium Arrests VEGFR2 Endocytosis, Preventing Angiogenic Signaling and Tumor Initiation. Developmental Cell. 2014;28(6):633–46. doi: 10.1016/j.devcel.2014.02.010 WOS:000333765900005. 24656741